drugset / Trial / NCT05178134
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
Phase 2
Completed
280 enrolled
Scandinavian Biopharma AB
Aurevia · collabGöteborg University · collabSahlgrenska University Hospital · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation of selected components of ETVAX.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2022-10-20
- Completion
- 2022-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etvax | Unknown | — | Oral |
Indications
No indication recorded.